Fast comment - Curasight announcement
Curasight enters into to partnership with Curium for uTrace in prostate cancer.
Curasight’s stock rise more than 20 percent today following the very important and positive announcement yesterday after the market close that the company has entered into an agreement with French based Curium to develop its uTRACE technology for prostate cancer until the product candidate gets approved in EU and US, while Curium will be responsible for manufacturing and commercialization. Curasight will receive up to USD 70 million in milestones based on development and commercialization progress and double-digit royalties on Curium sales in selected markets. Curasight will continue to have the right to develop and commercialize uTRACE for other indications outside prostate cancer area. With the agreement Curasight are finally able to confirm and validate the medical prospect and commercial potential of their uTRACE technology platform that investors have been waiting for. 👇
Read full announcement here: https://www.curasight.com/news/press-releases/2023/curasight-and-curium-announce-global-partnership-for-utrace-in-prostate-cancer/
Also, in our previously released One-Pager on Curasight it has been assumed that Curasight would be able to obtain external partnership deals as key to validate the uTRACE and later uTREAT technology platform.
Read the one-pager here: https://www.inderes.dk/research/curasight-one-pager-quick-overview-and-valuation
Disclaimer:
HC Andersen Capital receives payment from Curasight for a Digital IR/Corporate Visibility subscription agreement. /ANALYST Claus Thestrup 11:40 AM 05-02-2023.
Curasight is a Danish biotech company focusing on developing and improving the detection and treatment of cancer in a more gentle and efficient way. The company has two pipeline products that both use radionuclide (nuclear medicine) to facilitate better diagnosis and treatment of various cancer types; uTRACE use the so-called uPAR as a biomarker to diagnose the aggressiveness of cancer, and uTREAT use the uPAR as a attachment to treat the cancer. Based on good phase 2 data that has already been collected or will be in the first half of 2022, Curasight is expected to prepare phase 3 for uTRACE later in 2022 and 2023 for the following four cancer types: prostate, brain, neuroendocrine, and head and neck cancer.
Read more on company page